Skip to NavigationSkip to content

Abbvie and Google's Calico extend age-related disease partnership to $2.5bn

Published on 27/06/18 at 11:47am

The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development collaboration, originally signed in 2014, for another three years.

The $1.5 billion partnership has proven so successful that both Abbvie and Calico are to inject an additional $500 million each, with the latter responsible for research and early development until 2022 and pushing collaboration projects through Phase 2a until 2027. Abbvie will support Calico in these pursuits, and will be able to assume late-stage development and commercialisation in those candidates that make it past Phase 2a.

The project focuses on the development of interventions for age-related disease, including neurodegenerative conditions and cancer.

"We've built a successful collaboration – both scientifically and culturally – that is advancing cutting-edge science," said Dr Michael Severino, Executive Vice President, Research and Development, Chief Scientific Officer, at AbbVie. "Calico has attracted an outstanding team of world-class scientists and the extension of this collaboration allows us to further build on the research we've done to identify transformative treatment options for patients with age-related diseases."

Calico Chief Executive and former Genetech Chairman Dr Arthur D Levinson added: "Our collaboration with AbbVie has fully met our high expectations. Our initial agreement created a unique partnership and this extension will accelerate further our efforts to understand the science of aging to advance novel therapies for patients."

Matt Fellows

Comments

First of all - it's good to hear about prolonged cooperation with benefits for older people. They often seem forgotten, and you don't see many initiatives helping them feel needed, to spend their senility in good, fair conditions. Additionally, both companies rely on their good image and public opinion, so there is high chance, that what they offer will meet high social expectations. I  strongly support this project.

 

Regards,

James

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches